Ozurdex was found to be safe and effective for the treatment of diabetic macular edema in a real-life, prospective study.
The study included 54 eyes of 54 patients with DME refractory to previous treatment with anti-VEGFs. Ozurdex (dexamethasone intravitreal implant, Allergan) was injected under a sterile protocol, and re-injection was performed at 6 months in case of recurrent DME with decreased vision and/or increased central subfield thickness.
At the end of the 12-month follow-up, 31 patients (57.4%) had total resolution of macular edema. A mean improvement of 5.2 letters was reported.
Uncategorized